Cargando…

Predictive biomarkers for dasatinib treatment in melanoma

Dasatinib has anti-proliferative and anti-invasive effects in melanoma cell lines. However clinical trials have shown modest activity for dasatinib in metastatic melanoma. Although dasatinib targets SRC kinase, neither expression nor phosphorylation of SRC appears to predict response to dasatinib. I...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eustace, Alex J., Kennedy, Susan, Larkin, Anne-Marie, Mahgoub, Thamir, Tryfonopoulos, Dimitrios, O'Driscoll, Lorraine, Clynes, Martin, Crown, John, O'Donovan, Norma
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2014
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4278284/ https://www.ncbi.nlm.nih.gov/pubmed/25594008

Ejemplares similares

Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines
por: Eustace, Alex J, et al.
Publicado: (2008)

Membrane transport proteins in human melanoma: associations with tumour aggressiveness and metastasis
por: Walsh, N, et al.
Publicado: (2010)

Melanoma-associated antigen family protein-D4: clinical significance and functional relevance in breast cancer
por: Germano, S, et al.
Publicado: (2010)

The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, simvastatin, lovastatin and mevastatin inhibit proliferation and invasion of melanoma cells
por: Glynn, Sharon A, et al.
Publicado: (2008)

Kinase inhibitor screening identifies CDK4 as a potential therapeutic target for melanoma
por: MAHGOUB, T., et al.
Publicado: (2015)

Dasatinib Treatment Increases Sensitivity to c-Met Inhibition in Triple-Negative Breast Cancer Cells
por: Gaule, Patricia, et al.
Publicado: (2019)

In vitro Development of Chemotherapy and Targeted Therapy Drug-Resistant Cancer Cell Lines: A Practical Guide with Case Studies
por: McDermott, Martina, et al.
Publicado: (2014)

Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma
por: Walsh, Naomi, et al.
Publicado: (2009)

Alterations in integrin expression modulates invasion of pancreatic cancer cells
por: Walsh, Naomi, et al.
Publicado: (2009)

SNIP/p140Cap mRNA expression is an unfavourable prognostic factor in breast cancer and is not expressed in normal breast tissue
por: Kennedy, S, et al.
Publicado: (2008)

A method of separating extracellular vesicles from blood shows potential clinical translation, and reveals extracellular vesicle cargo gremlin-1 as a diagnostic biomarker
por: McNamee, Niamh, et al.
Publicado: (2021)

Investigation of the molecular profile of basal cell carcinoma using whole genome microarrays
por: O'Driscoll, Lorraine, et al.
Publicado: (2006)

Targeted treatment of advanced and metastaticbreast cancer with lapatinib
por: Corkery, Brendan, et al.
Publicado: (2008)

Identification of pancreatic cancer invasion-related proteins by proteomic analysis
por: Walsh, Naomi, et al.
Publicado: (2009)

BreastMark: An Integrated Approach to Mining Publicly Available Transcriptomic Datasets Relating to Breast Cancer Outcome
por: Madden, Stephen F, et al.
Publicado: (2013)

Mesenchymal Stem Cell Derived Extracellular Vesicles for Tissue Engineering and Regenerative Medicine Applications
por: Tsiapalis, Dimitrios, et al.
Publicado: (2020)

A Systems Biology Approach to Investigate Kinase Signal Transduction Networks That Are Involved in Triple Negative Breast Cancer Resistance to Cisplatin
por: Mukherjee, Nupur, et al.
Publicado: (2022)

The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer?
por: Duffy, Michael J, et al.
Publicado: (2011)

Resistance to HER2-targeted anti-cancer drugs is associated with immune evasion in cancer cells and their derived extracellular vesicles
por: Martinez, Vanesa G., et al.
Publicado: (2017)

miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer
por: Corcoran, Claire, et al.
Publicado: (2014)

The relevance of using 3D cell cultures, in addition to 2D monolayer cultures, when evaluating breast cancer drug sensitivity and resistance
por: Breslin, Susan, et al.
Publicado: (2016)

Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL
por: Eustace, Alex J, et al.
Publicado: (2018)

Extracellular vesicles from mesenchymal stem cells as a Covid-19 treatment
por: O’Driscoll, Lorraine
Publicado: (2020)

PP2A inhibition overcomes acquired resistance to HER2 targeted therapy
por: McDermott, Martina SJ, et al.
Publicado: (2014)

Correction: PP2A inhibition overcomes acquired resistance to HER2 targeted therapy
por: McDermott, Martina S. J., et al.
Publicado: (2023)

Identification of potential new treatment response markers and therapeutic targets using a Gaussian process-based method in lapatinib insensitive breast cancer models
por: Santra, Tapesh, et al.
Publicado: (2017)

Neratinib resistance and cross-resistance to other HER2-targeted drugs due to increased activity of metabolism enzyme cytochrome P4503A4
por: Breslin, Susan, et al.
Publicado: (2017)

Inhibiting extracellular vesicles formation and release: a review of EV inhibitors
por: Catalano, Mariadelva, et al.
Publicado: (2019)

Evidence for the Need to Evaluate More Than One Source of Extracellular Vesicles, Rather Than Single or Pooled Samples Only, When Comparing Extracellular Vesicles Separation Methods
por: Martinez-Pacheco, Sarai, et al.
Publicado: (2021)

Pre-Clinical In Vitro Models Used in Cancer Research: Results of a Worldwide Survey
por: Martinez-Pacheco, Sarai, et al.
Publicado: (2021)

miR-758-3p: a blood-based biomarker that’s influence on the expression of CERP/ABCA1 may contribute to the progression of obesity to metabolic syndrome
por: O’Neill, Sadhbh, et al.
Publicado: (2018)

Doxorubicin Loading into Milk and Mesenchymal Stem Cells’ Extracellular Vesicles as Drug Delivery Vehicles
por: Mukhopadhya, Anindya, et al.
Publicado: (2023)

Combined targeting EGFR and SRC as a potential novel therapeutic approach for the treatment of triple negative breast cancer
por: Canonici, Alexandra, et al.
Publicado: (2020)

Preclinical evaluation of Insulin-like growth factor receptor 1 (IGF1R) and Insulin Receptor (IR) as a therapeutic targets in triple negative breast cancer
por: Roche, Sandra, et al.
Publicado: (2023)

Extracellular vesicle separation from milk and infant milk formula using acid precipitation and ultracentrifugation
por: Mukhopadhya, Anindya, et al.
Publicado: (2021)

SIRT2 Contributes to the Resistance of Melanoma Cells to the Multikinase Inhibitor Dasatinib
por: Karwaciak, Iwona, et al.
Publicado: (2019)

Dasatinib Resensitizes MAPK Inhibitor Efficacy in Standard-of-Care Relapsed Melanomas
por: Rebecca, Vito W., et al.
Publicado: (2023)

Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08–10 trial
por: Gullo, Giuseppe, et al.
Publicado: (2019)

Docetaxel-Resistance in Prostate Cancer: Evaluating Associated Phenotypic Changes and Potential for Resistance Transfer via Exosomes
por: Corcoran, Claire, et al.
Publicado: (2012)

Melanoma and Sarcoidosis in Patients Receiving or Not Antineoplastic Therapy
por: Gouveris, Panagiotis, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_nqdc0f6ndokkuudv8d7curtc99